Skip to main content

Table 3 ‘Standard’ antibiotic use in patients developing MDRO, October 2018–October 2020

From: Patterns of multidrug resistant organism acquisition in an adult specialist burns service: a retrospective review

Organism

N

Antibiotic exposure† before MDRO isolation

Time in days between antibiotic exposure and MDRO isolation‡

MRSA

24

15 (62.5%)

23.7 (6.0–33.7)

VRE

 < 5

 < 5

–

Pseudomonas (Group 1)

33

24 (72.7%)

21.8 (14.2–35.5)

Pseudomonas (Group 2)

8

7 (87.5%)

17.0 (14.0–35.5)

CR Acinetobacter species

14

 < 5

–

CRE

 < 5

 < 5

–

ESBL-PE

16

11 (68.8%)

7.8 (2.9–22.7)

  1. Exposure before antibiotic data reported as frequency (percentage). Time between antibiotic exposure and MDRO isolation data reported as median (IQR). Excludes missing data
  2. †Standard’ antibiotics refer to antibiotics that are active against most/all isolates of specific organism other than the resistant phenotype of interest
  3. ‡Excludes patients who developed MDRO before exposure to category 1 antibiotics
  4. Carbapenem-resistant CRE Carbapenem-resistant Enterobacteriaceae; ESBL-PE Extended spectrum beta lactamase producing Enterobacteriaceae; IQR interquartile range; MDRO multi-drug resistant organism; MRSA Methicillin-resistant Staphylococcus aureus; VRE Vancomycin-resistant Enterococcus; Pseudomonas aeruginosa groups are defined by resistance to carbapenems (Group 1) or either piperacillin-tazobactam or cefepime (Group 2)
Back to article page

Antimicrobial Resistance & Infection Control

ISSN: 2047-2994

Contact us